This trial is examining the progression of RA and the effectiveness of clinical interventions using NIR-ICG imaging, which is a reliable and reproducible method.
- Rheumatoid Arthritis
1 Primary · 2 Secondary · Reporting Duration: 16 weeks
Awards & Highlights
2 Treatment Groups
Established RA (> 10 years of disease)
1 of 2
Early RA (<1 year of disease)
1 of 2
40 Total Participants · 2 Treatment Groups
Primary Treatment: MultiSpectral Imaging System · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is the research team engaging in patient recruitment for this trial?
"According to the information on clinicaltrials.gov, this experiment is currently not recruiting participants. It was first posted on December 30th 2021 and modified most recently January 20th 2022. Despite no open recruitment for this study at present, there are 379 other trials actively enrolling patients at this time." - Anonymous Online Contributor
Has the MultiSpectral Imaging System earned regulatory approval by the FDA?
"In accordance with the data provided from our organisation, Power, the MultiSpectral Imaging System is estimated to be of a low level safety rating (1), given that this study is in its first phase and there are limited clinical trials demonstrating efficacy." - Anonymous Online Contributor